The National Cancer Institute (NCI) is offering this U01 grant as part of its Targeting Fusion Oncoproteins in Childhood Cancers (TFCC) Network. This initiative aims to advance our understanding of how fusion oncoproteins drive pediatric cancers and to develop novel, targeted therapeutic approaches. The grant focuses on dissecting the molecular mechanisms by which these oncoproteins function, with the goal of identifying potential drug targets or critical dependencies. Research activities include characterizing fusion oncoprotein complexes, delineating their pathways, and exploring the roles of ncRNAs and post-translational modifications. Funding priority is given to applications addressing fusion oncoproteins in high-risk tumors, particularly pediatric solid and brain tumors, where targeted agents are lacking. U01 recipients will collaborate closely with UM1 grantees.
Opportunity ID: 349312
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-CA-23-036 |
| Funding Opportunity Title: | Mechanisms of Fusion-Driven Oncogenesis in Childhood Cancers (U01 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.396 — Cancer Biology Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jul 17, 2023 |
| Last Updated Date: | Jul 17, 2023 |
| Original Closing Date for Applications: | Nov 15, 2023 |
| Current Closing Date for Applications: | Nov 15, 2023 |
| Archive Date: | Dec 21, 2023 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $325,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Private institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments County governments Public housing authorities/Indian housing authorities City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Others (see text field entitled “Additional Information on Eligibility” for clarification) Public and State controlled institutions of higher education For profit organizations other than small businesses Small businesses Independent school districts |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | NCI is forming the Targeting Fusion Oncoproteins in Childhood Cancers (TFCC) Network to advance our understanding of the mechanisms of action of fusion oncoproteins in pediatric cancers and to apply novel chemical strategies for developing targeted therapeutic approaches. This RFA will use the U01 mechanism to solicit applications focused on molecular mechanisms by which fusion oncoproteins drive pediatric cancers with the goals of better understanding the biology of these cancers and identifying potential drug targets or critical dependencies. Examples of relevant research activities include, but are not limited to, dissecting pathways by which these fusion oncoproteins cause cancer, characterizing the composition and structure of fusion oncoprotein complexes, and delineating the roles of ncRNAs and post-translational modifications in fusion oncoprotein function. Funding priority will be given to applications that focus on fusion oncoproteins found in tumors that have high risk of treatment failure and for which there has been little progress in identifying targeted agents. Applications focused on pediatric solid tumors and brain tumors are particularly encouraged. U01 recipients will meet regularly with UM1 grantees funded through the Next Generation Chemistry Centers for Fusion Oncoproteins FOA. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-036.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 349312 Full Announcement-RFA-CA-23-036 -> RFA-CA-23-036-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00282584 | Oct 15, 2023 | Nov 15, 2023 | View |
Package 1
Mandatory forms
349312 RR_SF424_5_0-5.0.pdf
349312 PHS398_CoverPageSupplement_5_0-5.0.pdf
349312 RR_OtherProjectInfo_1_4-1.4.pdf
349312 PerformanceSite_4_0-4.0.pdf
349312 RR_KeyPersonExpanded_4_0-4.0.pdf
349312 PHS398_ResearchPlan_5_0-5.0.pdf
349312 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
349312 RR_Budget_3_0-3.0.pdf
349312 RR_SubawardBudget30_3_0-3.0.pdf
349312 PHS398_ModularBudget_1_2-1.2.pdf
349312 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
